Affiliation:
1. Department of Pharmacology, AIIMS Deoghar, India
Abstract
Lepra Reactions (LR) are inflammatory conditions with immune mediators that are highly morbid. Patients with the lepromatous end of the leprosy spectrum (BL-LL) are the only ones that develop type-2 LR. 90% of the time, it happens during or right after treatment, usually within two years. Here, we present a type-2 LR case. The sixty-year-old woman who was diagnosed with lepromatous leprosy (LL) after developing a hypopigmented skin lesion six months prior. She was treated twice at our hospital over the course of the previous six months after developing type-2 LR, which manifested as recurrent fever episodes, polyarthritis, erythema nodosum, and mononeuritis multiplex.
Publisher
Oriental Scientific Publishing Company
Reference7 articles.
1. 1. Sasaki, S., Takeshita, F., Okuda, K., & Ishii, N. (2001). Mycobacterium leprae and leprosy: a compendium. Microbiology and immunology, 45(11), 729–736. https://doi.org/10.1111/j.1348-0421.2001.tb01308.x
2. 2. Gelber RH. Leprosy (Hansens disease). In: Kasper DL, Braunwald E, Fauci AS, Longo DL, Jamison LJ, editors. Harrisons Principles of Internal Medicine.17th ed. New York: Mc Graw Hill;2008.p.1021-26.
3. 3. University of Texas M. D. Anderson Cancer Center. (2008, November 28). New Leprosy Bacterium: Scientists Use Genetic Fingerprint To Nail ‘Killing Organism’. ScienceDaily. Retrieved June 6, 2023 from www.sciencedaily.com/releases/2008/11/081124141047.htm
4. 4. Pocaterra, L., Jain, S., Reddy, R., Muzaffarullah, S., Torres, O., Suneetha, S., & Lockwood, D. N. (2006). Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. The American journal of tropical medicine and hygiene, 74(5), 868–879.
5. 5. Sethuraman, G., Jeevan, D., Srinivas, C. R., & Ramu, G. (2002). Bullous erythema nodosum leprosum (bullous type 2 reaction). International journal of dermatology, 41(6), 362–364.